Ardelyx Inc (NASDAQ:ARDX) CEO Michael Raab sold 23,128 shares of the firm's stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $7.01, for a total transaction of $162,127.28.
Michael Raab also recently made the following trade(s):
- On Monday, June 1st, Michael Raab sold 23,128 shares of Ardelyx stock. The stock was sold at an average price of $7.33, for a total transaction of $169,528.24.
- On Monday, May 4th, Michael Raab sold 15,941 shares of Ardelyx stock. The stock was sold at an average price of $7.01, for a total transaction of $111,746.41.
- On Friday, April 17th, Michael Raab sold 9,428 shares of Ardelyx stock. The shares were sold at an average price of $7.02, for a total value of $66,184.56.
- On Wednesday, April 15th, Michael Raab sold 500 shares of Ardelyx stock. The stock was sold at an average price of $7.03, for a total value of $3,515.00.
NASDAQ ARDX traded up $0.19 on Monday, hitting $7.02. 598,200 shares of the company were exchanged, compared to its average volume of 808,298. Ardelyx Inc has a 1-year low of $2.10 and a 1-year high of $8.81. The firm has a 50 day moving average of $7.07 and a two-hundred day moving average of $6.94. The company has a current ratio of 9.76, a quick ratio of 9.76 and a debt-to-equity ratio of 0.26. The company has a market cap of $631.40 million, a P/E ratio of -5.36 and a beta of 2.02.
Ardelyx (NASDAQ:ARDX) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.25). Ardelyx had a negative net margin of 1,403.90% and a negative return on equity of 77.23%. The company had revenue of $1.21 million during the quarter, compared to the consensus estimate of $0.90 million. Research analysts anticipate that Ardelyx Inc will post -1.05 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of ARDX. Ameritas Investment Partners Inc. boosted its position in Ardelyx by 60.4% in the 1st quarter. Ameritas Investment Partners Inc. now owns 5,443 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 2,050 shares during the last quarter. Meeder Asset Management Inc. boosted its holdings in Ardelyx by 43.2% in the fourth quarter. Meeder Asset Management Inc. now owns 6,969 shares of the biopharmaceutical company's stock valued at $52,000 after acquiring an additional 2,104 shares during the last quarter. State Board of Administration of Florida Retirement System bought a new position in Ardelyx in the first quarter valued at about $63,000. Victory Capital Management Inc. increased its position in Ardelyx by 21.0% in the fourth quarter. Victory Capital Management Inc. now owns 9,547 shares of the biopharmaceutical company's stock worth $68,000 after purchasing an additional 1,657 shares during the period. Finally, Caxton Associates LP bought a new stake in Ardelyx during the 4th quarter worth about $92,000. 86.08% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts have issued reports on ARDX shares. Cowen reiterated a "buy" rating on shares of Ardelyx in a research note on Wednesday, June 17th. BidaskClub lowered shares of Ardelyx from a "buy" rating to a "hold" rating in a report on Friday, May 29th. Zacks Investment Research cut shares of Ardelyx from a "buy" rating to a "hold" rating in a research report on Tuesday, June 2nd. Finally, ValuEngine raised shares of Ardelyx from a "sell" rating to a "hold" rating in a research note on Wednesday, March 18th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Ardelyx currently has a consensus rating of "Buy" and a consensus target price of $11.25.
Ardelyx, Inc, a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis.
Recommended Story: What is the NASDAQ Stock Market?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Stocks That Aggressive Investors Can Buy Now
There’s nothing like a steep market correction to test the risk appetite of even the most seasoned investor. With many investors seeing their 401k’s down 25%, 30% or more, it’s not surprising that many investors are taking money off the table.
And even during the most bullish market conditions, keeping some powder dry is a prudent decision.
But if you have an above-average risk appetite, then sitting on the sidelines is not your cup of tea. If you’re an investor with above-average risk tolerance, there are some opportunities to profit in this market. But you have to be looking in the right places.
At this time, the small-cap sector offers some interesting choices. Small-cap stocks are companies that have a market cap of less than $2 billion. Many of these stocks fall under the category of penny stocks, but that doesn’t make them bad. In some cases, they’re just obscure companies.
But right now, many investors will take growth wherever they can get it. And that’s why you should take a careful look at the 7 stocks we have in this presentation. The cost of entry is not high and the potential reward is worth your interest.
View the "7 Stocks That Aggressive Investors Can Buy Now".